HK Innoen's K‑Cap (Tegoprazan) Targets US Launch, Boosts Growth Prospects

Domestic new drug K‑Cap (ingredient tegoprazan) is moving into the US market, prompting analysts to view HK Innoen's growth focus shifting from domestic prescription expansion to the global arena. The US approval and launch are expected to trigger royalty income, and a potential European entry could further re‑evaluate the company's valuation. DS Investment Securities and iM Securities, in a report dated June 13, forecast Q2 results and identify the US entry of K‑Cap as the key mid‑ to long‑term growth driver for HK Innoen. DS Investment Securities projects a US launch in January of next year and highlights the value of the US business for K‑Cap.